6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05266417 (ClinicalTrials.gov)	February 7, 2022	23/2/2022	Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)	Parkinson Disease	Drug: INS-GSH;Drug: Matched Placebos	Gateway Institute for Brain Research	NULL	Recruiting	30 Years	85 Years	All	56	Phase 2	United States
2	NCT04251585 (ClinicalTrials.gov)	February 4, 2020	28/1/2020	Intranasal Insulin in Parkinson's Disease	Single Center Safety and Tolerability Trial of Intranasal Insulin in Parkinson's Disease	Parkinson Disease	Drug: Regular Novolin R;Drug: Placebo	HealthPartners Institute	NULL	Recruiting	41 Years	89 Years	All	30	Phase 2	United States
3	NCT04687878 (ClinicalTrials.gov)	January 1, 2020	28/12/2020	The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease Patients	Evaluating the Effect of Intranasal Insulin Administration on Motor and Non-motor Symptoms in Parkinson's Disease Patients; a Randomized Double-blinded Placebo-controlled Clinical Trial	Parkinson Disease	Drug: Insulin;Drug: Normal saline	dr.dargahi	NULL	Recruiting	17 Years	N/A	All	40	Phase 2	Iran, Islamic Republic of
4	NCT02064166 (ClinicalTrials.gov)	February 2014	13/2/2014	Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.	A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy	Parkinson Disease;Multiple System Atrophy	Drug: Intranasal Insulin	Peter Novak	NULL	Completed	18 Years	N/A	All	15	Phase 2	United States